Future Pharmacology, Vol. 3, Pages 296-316: Unraveling the Impact of Salbutamol Polytherapy: Clinically Relevant Drug Interactions

Future Pharmacology, Vol. 3, Pages 296-316: Unraveling the Impact of Salbutamol Polytherapy: Clinically Relevant Drug Interactions

Future Pharmacology doi: 10.3390/futurepharmacol3010019

Authors: Lara Marques Nuno Vale

The proper drug choice determines the treatment quality for a disease. The pharmacotherapeutic strategy for respiratory diseases often involves the combination of different drugs with different mechanisms of action. Salbutamol is a short-acting β2-agonist (SABA) used as a reliever in the treatment of asthma and is frequently paired with inhaled corticosteroids (ICS). Indeed, drug–drug interactions (DDI) receive special attention as they are some of the most common causes of adverse effects and can lead to increased morbidity and mortality. DDIs can occur in patients undergoing polytherapy at the pharmacokinetic (PK) or pharmacodynamic (PD) level. Given this, the interaction of salbutamol with other drugs has been extensively explored in terms of PD and PK since its introduction into the pharmaceutical market. To date, more than a thousand salbutamol interactions have been reported. Here, we propose to review some interactions of salbutamol with other drugs such as beta-blockers, anticholinergics, other classes of bronchodilators, corticosteroids, and others, and point out significant gaps in the knowledge of DDI.